Mainz Biomed (NASDAQ:QUCY) Rating Increased to Strong-Buy at Litchfield Hills Research

Mainz Biomed (NASDAQ:QUCY) was upgraded by stock analysts at Litchfield Hills Research to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Other research analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mainz Biomed in a research report on Friday. Wall Street Zen raised Mainz Biomed to a “hold” rating in a report on Saturday, June 6th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Mainz Biomed presently has a consensus rating of “Hold”.

Mainz Biomed Stock Down 3.5%

Shares of NASDAQ QUCY opened at $1.39 on Monday. The company’s 50 day moving average is $1.53. Mainz Biomed has a 52 week low of $0.30 and a 52 week high of $4.93. The firm has a market capitalization of $20.38 million, a PE ratio of -0.03 and a beta of 2.31.

Mainz Biomed Company Profile

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.